Brand Name Drug Negotiations Status

The pCPA is a part of the overall Canadian drug approval and reimbursement process. It starts with regulatory approval through Health Canada where drugs are evaluated for efficacy, quality and safety. Following a positive approval from Health Canada, all drugs then go through a health technology assessment for clinical and cost-effectiveness. In Canada there are two review boards:

For the majority of new drugs, the pCPA negotiation process begins once a recommendation is published by CADTH and/or INESSS.

Together with our partners, we have designed the pCPA Temporary Access Process (pTAP) that will allow patients to have temporary access to some drugs earlier. More information is available on our pTAP webpage.

Product Manufacturer Status Indication
Maviret (glecaprevir/pibrentasvir granules) AbbVie Corporation Concluded with an LOI Pediatric Chronic Hepatitis C
Remsima SC (infliximab) Celltrion Healthcare Canada Ltd. Under consideration for negotiation Crohn’s disease
Bimzelx (bimekizumab) UCB Canada Inc. Under consideration for negotiation Psoriatic arthritis
Bimzelx (bimekizumab) UCB Canada Inc. Under consideration for negotiation Ankylosing spondylitis
Epkinly (pTAP negotiation) (epcoritamab) AbbVie Corporation Active Negotiation For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL) or follicular lymphoma Grade 3B (FLG3b) after two or more lines of systemic therapy and who have previously received or are unable to receive CAR-T cell therapy.
Jemperli (dostarlimab) GlaxoSmithKline Inc. Under consideration for negotiation Jemperli (dostarlimab for injection) is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer who are candidates for systemic therapy.
Libtayo (cemiplimab) Sanofi Genzyme Under consideration for negotiation Libtayo (cemiplimab for injection):• in combination with platinum‐based chemotherapy for the first‐line treatment of adult patients with NSCLC whose tumours have no EGFR, ALK or ROS1 aberrations and is:- locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or - metastatic NSCLC.
To be confirmed (ustekinumab) Sandoz Canada Inc. Active Negotiation Multiple Indications
Wyost (denosumab 120 mg/1.7 mL) Sandoz Canada Inc. Concluded with an LOI Multiple Indications
Epidiolex (cannabidiol) Jazz Pharmaceuticals Canada Inc. Under consideration for negotiation Seizures associated with Tuberous Sclerosis Complex (TSC)
Epidiolex (cannabidiol) Jazz Pharmaceuticals Canada Inc. Under consideration for negotiation Dravet Syndrome (DS)
Leqvio (inclisiran) Novartis Pharmaceuticals Canada Inc. Under consideration for negotiation Primary hypercholesterolemia (non-familial and heterozygous familial) with atherosclerotic cardiovascular disease
Epidiolex (cannabidiol) Jazz Pharmaceuticals Canada Inc. Under consideration for negotiation Lennox-Gastaut Syndrome (LGS)
Remsima SC (infliximab) Celltrion Healthcare Canada Ltd. Under consideration for negotiation Ulcerative Colitis
Hemgenix (etranacogene dezaparvovec) CSL Behring Canada Inc. Under consideration for negotiation Hemophilia B
Tecvayli (teclistamab) Janssen Inc. Under consideration for negotiation Teclistamab injection is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
SIR-Spheres Y-90 resin microspheres (Yttrium-90 microspheres) Sirtex Medical Active Negotiation Hepatocellular carcinoma
TheraSphere Y-90 Glass Micropheres (Yttrium-90 microspheres) Boston Scientific Corporation Active Negotiation Hepatocellular carcinoma
Uplizna (inebilizumab) Horizon Therapeutics Canada Under consideration for negotiation Neuromyelitis optica spectrum disorders (NMOSD)
Slynd (drospirenone) Duchesnay Inc. Under consideration for negotiation Contraceptive, oral
Ultomiris (ravulizumab) Alexion Pharma Canada Corp. Under consideration for negotiation Neuromyelitis optica spectrum disorder (NMOSD)
Steqeyma (ustekinumab) Celltrion Healthcare Canada Ltd. Active Negotiation Multiple indications
Veklury (remdesivir) Gilead Sciences Canada Inc. Concluded with an LOI COVID-19
Lonsurf (trifluridine/tipiracil) Taiho Pharma Canada Inc. Active Negotiation LONSURF, in combination with bevacizumab, for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents.
Myalepta (metreleptin) Medison Pharma Canada Inc. Under consideration for negotiation Leptin deficiency in lipodystrophy
Trecondyv (treosulfan) Medexus Pharmaceuticals, Inc. Under consideration for negotiation In combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult patients with AML or MDS at increased risk for standard conditioning therapies.
Beqvez (fidanacogene elaparvovec) Pfizer Canada ULC Under consideration for negotiation Treatment of adults (aged 18 years or older) with moderately severe to severe Hemophilia B (congenital Factor IX deficiency) who are negative for neutralizing antibodies to variant AAV serotype Rh74
Rezurock (belumosudil) sanofi-aventis Canada Inc. Under consideration for negotiation For the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy.
Paxlovid (nirmatrelvir/ritonavir) Pfizer Canada ULC Concluded with an LOI Mild-to-moderate COVID-19, treatment
Columvi (glofitamab) Hoffmann-La Roche Limited Active Negotiation Glofitamab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from follicular lymphoma (trFL), or primary mediastinal B-cell lymphoma (PMBCL), who have received two or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T cell therapy or have previously received CAR-T cell therapy.
Polivy (Polatuzumab Vedotin) HOFFMANN-LA ROCHE LIMITED Under consideration for negotiation Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL.
Opdualag (nivolumab and relatlimab) Bristol Myers Squibb Under consideration for negotiation Opdualag (nivolumab and relatlimab) is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma who have not received prior systemic therapy for unresectable or metastatic melanoma
Trodelvy (sacituzumab govitecan) Gilead Sciences Canada Inc. Under consideration for negotiation The treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Lynparza (olaparib) AstraZeneca Canada Inc. Concluded with an LOI Olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).
Akeega (niraparib abiraterone acetate) Janssen Inc. Under consideration for negotiation Akeega is indicated with prednisone or prednisolone for: The treatment of adult patients with deleterious or suspected deleterious BRCA mutated (germline and/or somatic) metastatic castration resistant prostate cancer (mCRPC), who are asymptomatic/mildly symptomatic, and in whom chemotherapy is not clinically indicated. Patients must have confirmation of BRCA mutation before Akeega treatment is initiated.
Amvuttra (vutrisiran) Alnylam Netherlands B.V. Under consideration for negotiation Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis)
Bylvay (odevixibat) Medison Pharma Canada Inc. Under consideration for negotiation The treatment of pruritus in patients aged 6 months or older with progressive familial intrahepatic cholestasis (PFIC).
Rinvoq (upadacitinib) AbbVie Corporation Concluded with an LOI Crohn's disease
Doptelet (avatrombopag) Sobi Canada Inc. Under consideration for negotiation chronic immune thrombocytopenia
Imbruvica (ibrutinib) Janssen Inc. Under consideration for negotiation Waldenström’s macroglobulinemia
Asparlas (calaspargase pegol) Servier Canada Inc. Active Negotiation Acute Lymphoblastic Leukemia
Nucala (mepolizumab) GlaxoSmithKline Inc. Concluded with an LOI Add-on maintenance treatment of severe eosinophilic asthma in children (aged 6 years and older)
Pemazyre (pemigatinib) Incyte Biosciences Canada Corporation Active Negotiation For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement and a ECOG performance status of 0 to 2,
Adtralza (tralokinumab) LEO Pharma Inc. Under consideration for negotiation Atopic dermatitis
Vyvgart (efgartigimod alfa) Argenx Canada Inc. Active Negotiation Generalized myasthenia gravis (gMG)
Rybelsus (semaglutide) Novo Nordisk Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 2
Repatha (evolocumab) Amgen Canada Inc. Concluded with an LOI Primary hyperlipidemia and mixed dyslipidemia
Ozempic (semaglutide) Novo Nordisk Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 2
Atriance (nelarabine) Sandoz Canada Inc. Negotiations were not pursued Nelarabine (Atriance) for addition to front-line multi-agent therapy of pediatric, adolescent, and young adult (AYA) patients (aged 1 year to 30 years at diagnosis) with intermediate- or high-risk T-cell acute lymphoblastic leukemia (T-ALL).
Octasa (mesalamine DR) Pendopharm, a division of Pharmascience Inc. Concluded with an LOI Ulcerative Colitis
Livmarli (maralixibat) Mirum Pharmaceuticals Inc. Under consideration for negotiation Alagille syndrome
Sogroya (somapacitan) Novo Nordisk Canada Inc. Under consideration for negotiation Growth hormone deficiency
Evkeeza (evinacumab) Ultragenyx Pharmaceutical Inc. Under consideration for negotiation Homozygous familial hypercholesterolemia (HoFH)
Dupixent (dupilumab) Sanofi Genzyme Under consideration for negotiation Atopic dermatitis, pediatrics
Yescarta (axicabtagene ciloleucel) Gilead Sciences Canada Inc. Active Negotiation The treatment of adult patients with relapsed or refractory grade 1, 2 or 3a follicular lymphoma (FL) after two or more lines of systemic therapy.
Imfinzi and Imjudo (durvalumab and tremelimumab) ASTRAZENECA CANADA INC Concluded with an LOI Imjudo (tremelimumab for injection) in combination with durvalumab is indicated for the first-line treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who require systemic therapy.
Cabometyx (cabozantinib) Ipsen Biopharmaceuticals Active Negotiation Cabometyx in combination with nivolumab, is indicated for the first-line treatment of adult patients with advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC
Imbruvica (ibrutinib) Janssen Inc. Under consideration for negotiation Imbruvica with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL), including those with 17p deletion.
Lumakras (sotorasib) AMGEN CANADA INC Under consideration for negotiation KRAS G12C-mutated advanced NSCLC
Imcivree (setmelanotide) Rhythm Pharmaceuticals, Inc. Under consideration for negotiation Bardet-Biedl syndrome
Omvoh (mirikizumab) Eli Lilly Canada Inc. Active Negotiation Ulcerative Colitis
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Vertex Pharmaceuticals (Canada) Incorporated Concluded with an LOI Cystic fibrosis, F508del CFTR mutation, 2 years and older
Cablivi (caplacizumab) sanofi-aventis Canada Inc. Negotiations were not pursued acquired thrombotic thrombocytopenic purpura (aTTP)
Onivyde (irinotecan liposome) Ipsen Biopharmaceuticals Canada, Inc. Concluded without agreement Metastatic Pancreatic Cancer
Kymriah (tisagenlecleucel) Novartis Pharmaceuticals Canada Inc. Under consideration for negotiation Indicated for the treatment of adult patients with relapsed or refractory grade 1, 2, or 3a follicular lymphoma (FL) after two or more lines of systemic therapy.
Xcopri (cenobamate) Paladin Labs Inc. Active Negotiation Epilepsy, partial-onset seizures
Rinvoq (upadacitinib) AbbVie Corporation Concluded with an LOI Ulcerative Colitis
Brukinsa (zanubrutinib) BeiGene, Ltd. Concluded with an LOI For the treatment of adult patients with chronic lymphocytic leukemia (CLL).
Welireg (belzutifan) Merck Canada Inc. Active Negotiation For the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated non-metastatic renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or non-metastatic pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
Jubbonti (denosumab 60 mg/mL) Sandoz Canada Inc. Concluded with an LOI Multiple indications
Mezera (mesalazine) AVIR Pharma Inc. Concluded with an LOI Ulcerative Colitis
Zoryve (roflumilast) Arcutis Biotherapeutics, Inc. Active Negotiation Plaque psoriasis
Tavneos (avacopan) Otsuka Canada Pharmaceutical Inc. Under consideration for negotiation Antineutrophil cytoplasmic antibody-associated vasculitis
Sotyktu (deucravacitinib) Bristol-Myers Squibb Company Active Negotiation Psoriasis, moderate to severe plaque
Ultomiris (ravulizumab) Alexion Pharma GMBH Negotiations were not pursued AChR antibody-positive generalized Myasthenia Gravis
Tremfya (guselkumab) Janssen Inc. Concluded with an LOI Psoriasis, moderate to severe plaque
Korsuva (difelikefalin) Otsuka Canada Pharmaceutical Inc. Negotiations were not pursued For the treatment of moderate to severe pruritus associated with chronic kidney disease in adult patients on hemodialysis
Wezlana (ustekinumab) Amgen Canada Inc. Concluded with an LOI Multiple indications
Enhertu (trastuzumab deruxtecan) AstraZeneca Canada Inc. Concluded with an LOI Indicated as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer
Vyalev (foslevodopa foscarbidopa) AbbVie Corporation Concluded with an LOI For the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson's disease.
Verquvo (vericiguat) Bayer Inc. Active Negotiation For the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent heart failure decompensation event requiring hospitalization and/or intravenous diuretic therapy
Qulipta (atogepant) AbbVie Corporation Concluded with an LOI For the prevention of episodic migraine in adults
Sohonos (palovarotene) Ipsen Biopharmaceuticals Canada, Inc. Active Negotiation Fibrodysplasia Ossificans Progressiva
Rinvoq (upadacitinib) AbbVie Corporation Concluded with an LOI Ankylosing spondylitis
Koselugo (selumetinib) Alexion Pharma GMBH Active Negotiation For the treatment of pediatric patients aged 2 years and above, with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas
Rukobia (fostemsavir) ViiV Healthcare Concluded without agreement For use in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen due to resistance, intolerance or safety considerations
Skyrizi (risankizumab) AbbVie Corporation Concluded with an LOI For the treatment of adults with moderately to severely active Crohn's disease
Carvykti (ciltacabtagene autoleucel) Janssen Inc. Active Negotiation For the treatment of adult patients with multiple myeloma (MM) who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and who are refractory to their last treatment.
Jamteki (ustekinumab) Jamp Pharma Corporation Concluded with an LOI Multiple indications
Rylaze (crisantaspase recombinant) Jazz Pharmaceuticals Canada Inc. Concluded with an LOI For the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 year or older who have developed hypersensitivity to E. coli-derived asparaginase.
Lapelga (pegfilgrastim) Apobiologix, a Division of Apotex Inc. Concluded with an LOI To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drug.
Trurapi (insulin aspart) sanofi-aventis Canada Inc. Concluded with an LOI • the treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia (normally to be used in regimens together with an intermediate or long-acting insulin)
• continuous subcutaneous insulin infusion (CSII) in pump systems which are licensed in Canada for Trurapi insulin infusion
Camzyos (mavacamten) Bristol Myers Squibb Canada Inc. Active Negotiation Treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) Class II-III in adult patients.
Tecartus (brexucabtagene autoleucel) Gilead Sciences Canada Inc. Concluded with an LOI For treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
Opdivo (nivolumab) BRISTOL-MYERS SQUIBB CANADA Concluded with an LOI For the neoadjuvant treatment of adult patients with resectable NSCLC (tumours ≥4cm or node positive) when used in combination with platinum-doublet chemotherapy
Empaveli (pegcetacoplan) Sobi Canada Inc. Concluded with an LOI For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to, or are intolerant of, a C5 inhibitor
Ranopto (ranibizumab) Teva Canada Concluded with an LOI For the treatment of:
• neovascular (wet) age-related macular degeneration (AMD)
• visual impairment due to diabetic macular edema (DME)
• visual impairment due to macular edema secondary to retinal vein occlusion (RVO)
• visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM)
• visual impairment due to choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy
Kerendia (finerenone) Bayer Inc. Concluded with an LOI Adjunct to standard of care therapy for chronic kidney disease and type 2 diabetes
Lynparza (olaparib) AstraZeneca Canada Inc. Concluded with an LOI For the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy
Pluvicto (lutetium vipivotide tetraxetan) Advanced Accelerator Applications Active Negotiation For the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy.
Rybrevant (amivantamab) Janssen Inc. Concluded without agreement For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy
Ultomiris (ravulizumab) Alexion Pharma GMBH Concluded with an LOI Atypical hemolytic uremic syndrome
Lorbrena (lorlatinib) Pfizer Canada ULC Concluded with an LOI for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)
Orladeyo (berotralstat) BioCryst Pharmaceuticals Inc. Active Negotiation Hereditary angioedema
Keytruda (pembrolizumab) Merck Canada Inc. Concluded with an LOI For the treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy.
Imfinzi (durvalumab) AstraZeneca Canada Inc. Concluded with an LOI In combination with gemcitabine-based chemotherapy for the treatment of patients with locally advanced or metastatic biliary tract cancer (BTC)
Yescarta (axicabtagene ciloleucel) Gilead Sciences Canada Inc. Active Negotiation for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy
Oxlumo (lumasiran) Alnylam Netherlands B.V. Concluded with an LOI primary hyperoxaluria type 1
Dupixent (dupilumab) sanofi-aventis Canada Inc. Concluded with an LOI Asthma
Dupixent (dupilumab) sanofi-aventis Canada Inc. Concluded with an LOI Atopic dermatitis
Saphnelo (anifrolumab) AstraZeneca Canada Inc. Concluded with an LOI Systemic lupus erythematosus
Benlysta (belimumab) GlaxoSmithKline Inc. Concluded with an LOI Active lupus nephritis
Ferriprox (deferiprone) Chiesi Canada Corporation Concluded without agreement transfusional iron overload due to sickle cell disease or other anemias
Ozurdex (dexamethasone) AbbVie Corporation Negotiations were not pursued Diabetic Macular Edema
Beovu (brolucizumab) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Diabetic Macular Edema
Nubeqa (Darolutamide) Bayer Inc. Concluded with an LOI For the treatment of patients with metastatic castration sensitive prostate cancer (mCSPC) in combination with docetaxel
Dayvigo (lemborexant) Eisai Limited Concluded without agreement Insomnia
Blood glucose test strips (blood glucose test strips) Tykess Pharmaceuticals Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips ( blood glucose test strips) Dex Medical Distribution Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) Roche Diabetes Care, division of Hoffman-La Roche Ltd. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) Bionime USA Corporation Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Keytruda (pembrolizumab) Merck Canada Inc. Concluded with an LOI Pembrolizumab in combination with chemotherapy, for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumors express PD‐L1 (CPS ≥ 10) as determined by a validated test
Kimmtrak (tebentafusp) Medison Pharma Canada Inc. Concluded with an LOI For the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma
Dificid (fidaxomicin) Merck Canada Inc. Concluded with an LOI Clostridium difficile infection
Ruzurgi (Amifampridine) Médunik Canada Inc. Concluded with an LOI Lambert-Eaton myasthenic syndrome (LEMS)
Radicava (edaravone) Mitsubishi Tanabe Pharma Canada, Inc. Concluded with an LOI amyotrophic lateral sclerosis
Vyepti (eptinezumab) Lundbeck Canada Inc. Concluded with an LOI Prevention of migraine
Uceris (budesonide) Bausch Health, Canada Inc. Concluded with an LOI Active mild to moderate distal ulcerative colitis
Zepzelca (lurbinectedin) Jazz Pharmaceuticals Canada Inc. Negotiations were not pursued For the treatment of adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy
Wakix (pitolisant hydrochloride) Paladin Labs Inc. Concluded without agreement For the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy
Blood glucose test strips (blood glucose test strips) Tremblay Harrison Inc. Concluded without agreement Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) sanofi-aventis Canada Inc. Concluded without agreement Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) Novo Biomedical Canada Ltd. Concluded without agreement Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) Auto Control Medical Inc Concluded without agreement Diabetes Mellitus, Type 1 & 2
Keytruda (pembrolizumab) Merck Canada Concluded with an LOI for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD‐L1 (CPS ≥ 1) as determined by a validated test, in combination with chemotherapy with or without bevacizumab
Zeposia (ozanimod) Celgene Inc. Concluded with an LOI Ulcerative Colitis
Tremfya (guselkumab) Janssen Inc. Concluded with an LOI Psoriatic Arthritis
Nucala (mepolizumab) GlaxoSmithKline Inc. Concluded with an LOI Severe chronic rhinosinusitis with nasal polyps
Tezspire (tezepelumab) AstraZeneca Canada Inc. Concluded with an LOI add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma
Xydalba (dalbavancin) Paladin Labs Inc. Concluded with an LOI Acute bacterial skin and skin structure infections
Rymti (etanercept) Lupin Pharma Canada Ltd. Concluded with an LOI ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis and polyarticular juvenile idiopathic arthritis
Vraylar (cariprazine) AbbVie Corporation Negotiations were not pursued bipolar disorder
Palynziq (pegvaliase) BioMarin Pharmaceutical Inc. Active Negotiation Phenylketonuria
Keytruda (pembrolizumab) Merck Canada Concluded with an LOI for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection
Livtencity (maribavir) Takeda Canada Inc. Concluded with an LOI post-transplant cytomegalovirus (CMV) infection/disease
Rozlytrek (Entrectinib) HOFFMANN-LA ROCHE LIMITED Concluded with an LOI For the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options
Cabometyx (cabozantinib) Ipsen Biopharmaceuticals Concluded with an LOI For the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory (RAI-R) or ineligible
Jardiance (empagliflozin) Boehringer Ingelheim (Canada) Ltd. Under consideration for negotiation adjunct to standard of care therapy for the treatment of chronic heart failure in adults
Vabysmo (faricimab) Hoffmann-La Roche Limited Concluded with an LOI diabetic macular edema (DME)
Minjuvi (tafasitamab) Incyte Biosciences Canada Corporation Concluded with an LOI in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant
Retevmo (selpercatinib) Eli Lilly Canada Inc. Concluded with an LOI For the treatment of rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.
Enhertu (trastuzumab deruxtecan) AstraZeneca Canada Inc. Concluded with an LOI For the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received a prior treatment with an anti-HER2-based regimen in the metastatic setting or developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy
Opdivo (nivolumab) Bristol Myers Squibb Canada Inc. Concluded with an LOI Indicated as monotherapy for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC
Verzenio (abemaciclib) Eli Lilly Canada Inc. Concluded with an LOI in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features and a Ki-67 score ≥20%
Keytruda (pembrolizumab) Merck Canada Concluded with an LOI For the adjuvant treatment of adult patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
Gavreto (pralsetinib) Hoffmann-La Roche Limited Concluded without agreement For the treatment of adult patients with rearranged during transfection (RET) fusion-positive locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC)
Lutathera (lutetium 177 dotatate) Advanced Accelerator Applications Concluded with an LOI For the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor (SSR)–positive pancreatic neuroendocrine tumours (pNETs) in adults whose disease has progressed after treatment with a somatostatin analogue (SSA), unless there is a contraindication or intolerance
Wegovy (semaglutide) Novo Nordisk Canada Inc. Negotiations were not pursued chronic weight management
Jakavi (ruxolintib) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI acute graft-versus-host disease
Lenvima (lenvatinib) Eisai Limited Concluded with an LOI In combination with pembrolizumab, for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation
Keytruda (pembrolizumab) Merck Canada Concluded with an LOI in combination with Lenvatinib (Lenvima) for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation.
Keytruda (pembrolizumab) Merck Canada Concluded with an LOI For the treatment of adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery
Byooviz (ranibizumab) Biogen Canada Inc. Concluded with an LOI Treatment of:
• neovascular (wet) age-related macular degeneration (AMD)
• visual impairment due to diabetic macular edema (DME)
• visual impairment due to macular edema secondary to retinal vein occlusion (RVO)
• visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM)
• visual impairment due to choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy
Spinraza (nusinersen) Biogen Canada Inc. Negotiations were not pursued spinal muscular atrophy (SMA) in patients aged 18 years or older
Tecentriq (atezolizumab) Hoffmann-La Roche Concluded with an LOI Indicated as monotherapy for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage II to IIIA (per the American Joint Committee on Cancer [AJCC], 7th edition) non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TCs) and do not have EGFR or ALK genomic tumour aberrations
Tepmetko (tepotinib) EMD Serono Canada, a division of EMD Inc. Concluded with an LOI For the treatment of adult patients with locally advanced unresectable metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations
Jemperli (dostarlimab) GlaxoSmithKline Inc. Negotiations were not pursued For the treatment of adult patients mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum containing regimen
Cibinqo (abrocitinib) Pfizer Canada ULC Concluded with an LOI moderate to severe atopic dermatitis
Poteligeo (mogamulizumab) Kyowa Kirin Canada, Inc. Concluded with an LOI mycosis fungoides (MF), Sézary syndrome (SS)
Vabysmo (faricimab) Hoffmann-La Roche Limited Concluded with an LOI neovascular (wet) age-related macular degeneration (nAMD)
Vraylar (cariprazine) AbbVie Corporation Concluded with an LOI schizophrenia in adults
Kirsty (insulin aspart) BGP Pharma ULC, d.b.a. Viatris Canada Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Brukinsa (zanubrutinib) BeiGene, Ltd. Negotiations were not pursued For the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Xpovio (selinexor) Forus Therapeutics Inc. Concluded with an LOI For the treatment of adult patients, in combination with bortezomib (V) and dexamethasone (d), with multiple myeloma (MM) who have received at least one prior therapy.
Scemblix (asciminib) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors
Vegzelma (bevacizumab) Celltrion Healthcare Canada Ltd. Concluded with an LOI For the treatment of: Metastatic Colorectal Cancer (mCRC); Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC); Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; and Malignant Glioma (WHO Grade IV) – Glioblastoma
Inqovi (Decitabine-Cedazuridine) Taiho Pharma Canada, Inc. Concluded with an LOI Treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups
Jakavi (ruxolintib) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI chronic graft-versus-host disease
Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) Amylyx Canada Concluded with an LOI amyotrophic lateral sclerosis (ALS)
Breyanzi (lisocabtagene maraleucel) Celgene Inc. Concluded with an LOI Adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma
Nexviazyme (avalglucosidase alfa) sanofi-aventis Canada Inc. Concluded without agreement late-onset Pompe disease
Retevmo (selpercatinib) Eli Lilly Canada Inc. Concluded with an LOI monotherapy treatment of rearranged during transfection (RET) fusion-positive differentiated thyroid carcinoma (DTC) in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib
Keytruda (pembrolizumab) Merck Canada Concluded with an LOI in combination with Lenvima, for the treatment of adult patients with advanced or metastatic renal cell carcinoma (RCC) with no prior systemic therapy for metastatic RCC
Lenvima (lenvatinib) Eisai Limited Concluded with an LOI In combination with pembrolizumab, for the treatment of adult patients with advanced or metastatic renal cell carcinoma (RCC) with no prior systemic therapy for metastatic renal cell carcinoma (RCC)
Vyndaqel (tafamidis) Pfizer Canada ULC Concluded with an LOI Cardiomyopathy due to transthyretin-mediated amyloidosis
Firdapse (amifampridine phosphate) KYE Pharmaceuticals Inc. Concluded with an LOI Lambert-Eaton Myasthenic Syndrome (LEMS) in adults
pdp-Amlodipine (amlodipine) Pendopharm, a division of Pharmascience Inc. Concluded with an LOI Treatment of mild to moderate essential hypertension and management of chronic stable angina
Arazlo (tazarotene) Bausch Health, Canada Inc. Concluded with an LOI acne vulgaris
Bryhali (halobetasol propionate) Bausch Health, Canada Inc. Concluded with an LOI corticosteroid-responsive dermatoses and the topical treatment of plaque psoriasis
Rinvoq (upadacitinib) AbbVie Corporation Concluded with an LOI Atopic dermatitis
Elonox and Elonox HP (enoxaparin sodium) Fresenius Kabi Canada Ltd. Concluded with an LOI Prevention or treatment of thrombosis and cardiovascular conditions
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Vertex Pharmaceuticals (Canada) Incorporated Concluded with an LOI Cystic Fibrosis, F508del CFTR mutation in patients aged 6 years and older
Libtayo (cemiplimab) sanofi-aventis Canada Inc. Concluded without agreement For the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC
Osphena (ospemifene) Duchesnay Inc. Concluded without agreement dyspareunia and/or vaginal dryness
Nypozi (filgrastim) Tanvex BioPharma USA, Inc. Concluded with an LOI Prevention or treatment of neutropenia in various indications
Semglee (Insulin Glargine) BGP Pharma ULC, d.b.a. Viatris Canada Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) ForaCare Technology Canada, Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) Skymed Monitors Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) MediSure Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) LifeScan Canada ULC Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) I-Sens, Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) BTNX Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) Ascensia Diabetes Care Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) Spirit Healthcare Group Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Blood glucose test strips (blood glucose test strips) Abbott Diabetes Care Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Retevmo (selpercatinib) Eli Lilly Canada Inc. Concluded with an LOI indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients
Qinlock (ripretinib) Medison Pharma Canada Inc. Concluded with an LOI For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib
Insulin pumps and pump supplies (insulin pumps and pump supplies) Insulet Canada Corporation Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Insulin pumps and pump supplies (Insulin pumps and pump supplies) Ypsomed Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Insulin pumps and pump supplies (Insulin pumps and pump supplies) Medtronic Canada Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Intrarosa (prasterone) Lupin Pharma Canada Ltd. Concluded without agreement postmenopausal vulvovaginal atrophy
Tavalisse (fostamatinib) Medison Pharma Canada Negotiations were not pursued chronic immune thrombocytopenia
Bimzelx (bimekizumab) UCB Canada Inc. Concluded with an LOI psoriasis, moderate to severe plaque
Pemazyre (pemigatinib) Incyte Biosciences Canada Corporation Negotiations were not pursued adults with previously treated, unresectable locally advanced or metastatic CCA with a FGFR2 fusion or other rearrangement
Lorbrena (lorlatinib) Pfizer Canada ULC Concluded without agreement Monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)
Adtralza (tralokinumab) LEO Pharma Inc. Negotiations were not pursued atopic dermatitis
Myinfla (colchicine) Pendopharm, a division of Pharmascience Inc. Negotiations were not pursued atherothrombotic events in coronary artery disease
Ngenla (somatrogon) Pfizer Canada ULC Concluded with an LOI Growth hormone deficiency
Libtayo (cemiplimab) Sanofi Genzyme Concluded without agreement For the treatment of patients with locally advanced or metastatic basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor.
Opdivo (nivolumab) Bristol Myers Squibb Canada Inc. Concluded with an LOI Opdivo — in combination with fluoropyrimidine- and platinum-containing chemotherapy — for the treatment of adult patients with advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma
Keytruda (pembrolizumab) Merck Canada Concluded with an LOI First-line treatment of locally advanced unresectable or metastatic, carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma in combination with platinum and fluoropyrimidine based chemotherapy, in adult patients
Leqvio (inclisiran) Novartis Pharmaceuticals Canada Inc. Under consideration for negotiation Primary hypercholesterolemia (non-familial and heterozygous familial)
Ultomiris (ravulizumab) Alexion Pharma Canada Corp. Concluded with an LOI Paroxysmal nocturnal hemoglobinuria (PNH)
Bijuva (estradiol and progesterone) Knight Therapeutics Inc. Concluded with an LOI vasomotor symptoms associated with menopause
Waymade-Trientine (trientine hydrochloride) Waymade Canada Inc  Concluded with an LOI Wilson's Disease
Vectibix (panitumumab) Amgen Canada Inc. Concluded with an LOI For the treatment of metastatic colorectal cancer
Phesgo SC (perjeta and herceptin) HOFFMANN-LA ROCHE LIMITED Concluded without agreement For the first-line treatment of patients with HER2-positive metastatic breast cancer
Darzalex SC (Daratumumab) Janssen Inc. Concluded with an LOI Darzalex SC in combination with bortezomib, cyclophosphamide, and dexamethasone, for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.
Trodelvy (sacituzumab govitecan) Gilead Sciences Canada Inc. Concluded with an LOI For the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior therapies, at least one of them for metastatic disease
Sarclisa (Isatuximab) Sanofi Genzyme Concluded with an LOI In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy
Piqray (alpelisib) Novartis Pharmaceuticals Canada Inc. Concluded without agreement In combination with fulvestrant, is indicated for the treatment of postmenopausal women and men, with hormone receptor-positive, HER2-negative, PIK3CA mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen
Opdivo (nivolumab) Bristol Myers Squibb Canada Inc. Concluded with an LOI For the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer in patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT)
Perjeta (pertuzumab) HOFFMANN-LA ROCHE LIMITED  Concluded without agreement In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either 2 cm in diameter or node positive)
Increlex (mecasermin) Ipsen Biopharmaceuticals Canada, Inc. Concluded with an LOI severe primary insulin-like growth factor-1 deficiency
Dojolvi (triheptanoin) Ultragenyx Canada Inc. Concluded with an LOI long-chain fatty acid oxidation disorders
Trazimera (trastuzumab) Pfizer Canada ULC Concluded with an LOI Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Herzuma (trastuzumab) Teva Canada Limited Concluded with an LOI Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Ogivri (trastuzumab) BGP Pharma ULC Concluded with an LOI Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Kanjinti (trastuzumab) Amgen Canada Inc. Concluded with an LOI Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Imvexxy (estradiol) Knight Therapeutics Inc. Concluded with an LOI postmenopausal moderate to severe dyspareunia
Tagrisso (osimertinib) AstraZeneca Canada Inc. Concluded with an LOI Indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations
Opdivo-Yervoy (nivolumab-ipilimumab) Bristol Myers Squibb Canada Inc. Concluded with an LOI Nivolumab, in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations
Kyprolis (carfilzomib) Amgen Canada Inc. Concluded with an LOI Treatment of multiple myeloma (including relapsed)
Padcev (enfortumab vedotin) Seagen Canada Inc. Concluded with an LOI For the treatment of adult patients with unresectable, locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and programmed death receptor-1 or programmed death-ligand 1 inhibitor therapy.
Ontruzant (trastuzumab) Organon Canada Inc. Concluded with an LOI Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease; Early Breast Cancer (EBC); Metastatic Breast Cancer (MBC); and Metastatic Gastric Cancer (MGC)
Mvasi (bevacizumab) Amgen Canada Inc. Concluded with an LOI first-line treatment of patients with metastatic carcinoma of the colon or rectum, in combination with fluoropyrimidine based chemotherapy / For treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer, in combination with carboplatin/paclitaxel chemotherapy regimen
Opsynvi (macitentan and tadalafil) Janssen Inc. Concluded without agreement pulmonary arterial hypertension
Emgality (galcanezumab) Eli Lilly Canada Inc. Concluded with an LOI Prevention of migraine
Reblozyl (luspatercept) Celgene Inc. Concluded with an LOI myelodysplastic syndromes associated anemia
Brukinsa (zanubrutinib) BeiGene, Ltd. Concluded with an LOI Waldenström’s macroglobulinemia
Ledaga (chlormethine hydrochloride) Recordati Rare Diseases Canada Inc. Concluded without agreement For the treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL)
Evenity (romosozumab) Amgen Canada Inc. Concluded with an LOI osteoporosis
MAR-Trientine (trientine) Marcan Pharmaceuticals Inc. Concluded with an LOI Wilson's Disease
Tukysa (tucatinib) Seagen Canada Inc. Concluded with an LOI Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination
Abecma (idecabtagene vicleucel) Celgene Inc. Negotiations were not pursued For the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment
Zaxine (rifaximin) Lupin Pharma Canada Limited Concluded with an LOI Hepatic Encephalopathy
Keytruda (pembrolizumab) Merck Canada Concluded with an LOI Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT
Aybintio (bevacizumab) Organon Canada Inc. Concluded with an LOI For the treatment of: Metastatic Colorectal Cancer (mCRC); Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC); Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; and Malignant Glioma (WHO Grade IV) – Glioblastoma
Onureg (azacitidine) Celgene Inc. Concluded with an LOI Maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT)
Abrilada (adalimumab) Pfizer Canada ULC Concluded with an LOI Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Yuflyma (adalimumab) Celltrion Healthcare Canada Ltd. Concluded with an LOI Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Kirsty (insulin aspart) BGP Pharma ULC, d.b.a. Viatris Canada Concluded without agreement Diabetes Mellitus, Type 1 & 2
Givlaari (givosiran) Alnylam Netherlands B.V. Concluded with an LOI acute hepatic porphyria
Xeomin (incobotulinumtoxinA) Merz Therapeutics Canada Concluded without agreement chronic sialorrhea associated with neurological disorders
Perseris (risperidone) HLS Therapeutics Inc. Concluded without agreement Schizophrenia
Inqovi (Decitabine-Cedazuridine) Taiho Pharma Canada, Inc. Concluded without agreement Inqovi (decitabine and cedazuridine) is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups
Saxenda (liraglutide) Novo Nordisk Canada Inc. Negotiations were not pursued chronic weight management
Vitrakvi (larotrectinib) Bayer Inc. Concluded with an LOI For the treatment of adult and pediatric patients with solid tumours that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.
Breztri Aerosphere (budesonide/glycopyrronium/ formeterol fumarate dihydrate) ASTRAZENECA CANADA INC Concluded with an LOI Chronic Obstructive Pulmonary Disease
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Vertex Pharmaceuticals (Canada) Incorporated Concluded with an LOI Cystic Fibrosis, F508del CFTR mutation
Vyxeos (daunorubicin and cytarabine) Jazz Pharmaceuticals Canada Inc. Concluded with an LOI For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Tecartus (brexucabtagene autoleucel) Gilead Sciences Canada Inc. Concluded with an LOI For the treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi)
Evrysdi (risdiplam) HOFFMANN-LA ROCHE LIMITED  Concluded with an LOI Spinal Muscular Atrophy
Rinvoq (upadacitinib) AbbVie Corporation Concluded with an LOI Psoriatic Arthritis
Entuzity KwikPen (human insulin) Eli Lilly Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Jorveza (budesonide) AVIR Pharma Inc. Concluded without agreement eosinophic esophagitis (maintenance)
Venclexta (venetoclax) AbbVie Corporation Negotiations were not pursued Venclexta in combination with low-dose cytarabine is indicated for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy
Venclexta (venetoclax) AbbVie Corporation Concluded with an LOI in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy
Entresto (sacubitril/valsartan) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Heart failure, NYHA class II or III
Opdivo-Yervoy (nivolumab-ipilimumab) Bristol Myers Squibb Canada Inc. Concluded with an LOI OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable malignant pleural mesothelioma (MPM) who have not received prior systemic therapy for MPM
Keytruda (pembrolizumab) Merck Canada Concluded with an LOI For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)
Imfinzi (durvalumab) AstraZeneca Canada Inc. Concluded with an LOI IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)
Braftovi (encorafenib) Pfizer Canada ULC Concluded with an LOI Braftovi in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy,
Braftovi/Mektovi (encorfenib/binimetinib) Pfizer Canada ULC Concluded with an LOI Braftovi (encorafenib) and Mektovi (binimetinib), in combination, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test
Unituxin (dinutuximab) United Therapeutics Concluded with an LOI high-risk neuroblastoma patients in their first relapse or determination of refractory disease, in combination with irinotecan, temozolomide, and granulocyte macrophage colony-stimulating factor
Inrebic (fedrantinib) Celgene Inc. Concluded with an LOI Treatment of splenomegaly and/or disease-related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib
Zeposia (ozanimod) Celgene Inc. Negotiations were not pursued Relapsing-Remitting Multiple Sclerosis
Rybelsus (semaglutide) Novo Nordisk Canada Inc. Concluded without agreement Diabetes Mellitus, Type 2
Insulin pumps and pump supplies (Insulin pumps and pump supplies) Tandem Diabetes Care Canada, Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Veltassa (patiromer) Otsuka Canada Pharmaceuticals Inc. Concluded without agreement hyperkalemia
Reblozyl (luspatercept) Celgene Inc. Concluded with an LOI beta-thalassemia associated anemia
Dupixent (dupilumab) Sanofi Genzyme Concluded without agreement Asthma
Tafinlar/Mekinist (dabrafenib/trametinib) Novartis Pharmaceuticals Canada Inc. Concluded without agreement Non-small cell lung cancer: for the treatment of metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation and who have not received any prior anti-cancer therapy for metastatic disease
Ilumya (tildrakizumab) Sun Pharma Canada Inc. Concluded with an LOI Psoriasis, moderate to severe plaque
Simlandi (adalimumab) Jamp Pharma Corporation Concluded with an LOI Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Corzyna (ranolazine) KYE Pharmaceuticals Inc. Concluded without agreement angina pectoris
Zejula (Niraparib) GlaxoSmithKline Inc. Concluded with an LOI Ovarian Cancer: Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy
Odomzo (sonidegib) Sun Pharma Canada Inc. Negotiations were not pursued Basal Cell Carcinoma (BCC): For the treatment of adult patients with histologically confirmed laBCC that is not amenable to radiation therapy or curative surgery
Bambevi (bevacizumab) Apotex Inc. Concluded with an LOI Metastatic Colorectal Cancer (mCRC) Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer Malignant Glioma (WHO Grade IV) - Glioblastoma
Polivy (Polatuzumab Vedotin) HOFFMANN-LA ROCHE LIMITED Concluded with an LOI In combo with bendamustine & rituximab is indicated for the treatment of adult patients with relapsed or refractory DLBCL, not otherwise specified, who are not eligible for autologous stem cell transplant & have received at least one prior therapy.
Alunbrig (brigatinib) Takeda Canada Inc. Concluded with an LOI For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor
Lynparza (olaparib) AstraZeneca Canada Inc. Concluded with an LOI Monotherapy for the treatment of adult patients with mCRPC & deleterious or suspected deleterious germline/somatic mutations in the HRR genes BRCA or ATM who have progressed following prior treatment with a NHA
Rozlytrek (Entrectinib) HOFFMANN-LA ROCHE LIMITED Concluded with an LOI ROS1-positive Non-Small Cell Lung Cancer
Ruzurgi (Amifampridine) Médunik Canada Inc. Concluded without agreement Lambert-Eaton myasthenic syndrome (LEMS)
Enspryng (satralizumab) Hoffmann-La Roche Limited Concluded with an LOI neuromyelitis optica spectrum disorders (NMOSD)
Osnuvo (teriparatide) AVIR Pharma Inc. Concluded with an LOI osteoporosis
Sarclisa (Isatuximab) Sanofi Genzyme Concluded with an LOI Isatuximab in combination with pomalidomide and dexamethasone, for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Remsima SC (infliximab) Celltrion Healthcare Canada Ltd. Concluded without agreement Rheumatoid Arthritis
Abevmy (bevacizumab) BGP Pharma ULC Concluded with an LOI Metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung Cancer (NSCLC), platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, and glioblastoma
Bavencio (avelumab) EMD Serono a Division of EMD Inc. Canada Concluded with an LOI Indicated for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy
Ajovy (fremanezumab) Teva Canada Innovation Concluded with an LOI prevention of migraine in adults
Entresto (sacubitril/valsartan) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Heart failure, NYHA class II or III
Calquence (Acalabrutinib) ASTRAZENECA CANADA INC Concluded with an LOI Chronic Lymphocytic Leukemia (CLL) (previously untreated): With or without obinutuzumab, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) for whom a fludarabine-based regimen is inappropriate
Calquence (Acalabrutinib) ASTRAZENECA CANADA INC Concluded with an LOI Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Kynmobi (apomorphine hydrochloride) Sunovion Pharmaceuticals Canada Inc. Concluded with an LOI Parkinson's disease
Kesimpta (ofatumumab) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Relapsing-Remitting Multiple Sclerosis
Ofev (nintedanib) Boehringer Ingelheim (Canada) Ltd. Concluded with an LOI Chronic fibrosing interstitial lung diseases
Darzalex SC (Daratumumab) Janssen Inc. Concluded with an LOI Multiple Myeloma
Daurismo (Glasdegib) Pfizer Canada ULC Negotiations were not pursued Acute Myeloid Leukemia (AML)
pdp-levETIRAcetam (levetiracetam) Pendopharm, a division of Pharmascience Inc. Concluded with an LOI Epilepsy
Zolgensma (onasemnogene abeparvovec) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Spinal Muscular Atrophy
Tecentriq and bevacizumab (Atezolizumab & Bevacizumab) HOFFMANN-LA ROCHE LIMITED Concluded with an LOI TECENTRIQ (atezolizumab), in combination with AVASTIN (bevacizumab), for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy.
Keytruda (pembrolizumab) Merck Canada Concluded with an LOI Head and Neck Squamous Cell Carcinoma (HNSCC)
Forxiga (dapagliflozin) AstraZeneca Canada Inc. Concluded with an LOI Heart failure, NYHA class II or III
Entyvio (SC) (vedolizumab) Takeda Canada Inc. Concluded with an LOI Crohn's disease
Venclexta (venetoclax) AbbVie Corporation Concluded with an LOI Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible
Adcetris (brentuximab vedotin) Seattle Genetics Inc. Concluded with an LOI Hodgkin's Lymphoma
Adcetris (brentuximab vedotin) Seattle Genetics Inc. Concluded with an LOI Primary Cutaneous Anaplastic Large Cell Lymphoma (or CD30- Expressing Mycosis Fungoides)
Spravato (esketamine hydrochloride) JANSSEN INC Negotiations were not pursued Major Depressive Disorder
Blincyto (blinatumomab) Amgen Canada Inc. Concluded with an LOI Minimal Residual Disease (MRD)-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL)
Riabni (rituximab) Amgen Canada Inc. Concluded with an LOI Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA)
Inclunox (enoxaparin) Sandoz Canada Inc. Concluded with an LOI Deep vein thrombosis (treatment and prevention)
Noromby (enoxaparin) Juno Pharmaceuticals Corp. Concluded with an LOI Deep vein thrombosis (treatment and prevention)
Nyvepria (pegfilgrastim) Pfizer Canada ULC Concluded with an LOI febrile neutropenia in non-myeloid malignancies
Trurapi (insulin aspart) sanofi-aventis Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Foquest (methylphenidate) Elvium Life Sciences Concluded with an LOI Attention-deficit/hyperactivity disorder (ADHD)
Suboxone (film) (buprenorphine and naloxone) Indivior UK Limited Concluded with an LOI Opioid drug dependence
Atectura Breezhaler (indacaterol /mometasone furoate) Valeo Pharma Inc. Concluded with an LOI Asthma
Enerzair Breezhaler (indacaterol/glycopyrronium/mometasone furoate) Valeo Pharma Inc. Concluded with an LOI Asthma
Luxturna (voretigene neparvovec) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Vision loss, inherited retinal dystrophy
Hadlima (adalimumab) Merck Concluded with an LOI Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Idacio (adalimumab) Fresenius Kabi Canada Ltd. Concluded with an LOI Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Hyrimoz (adalimumab) Sandoz Canada Inc. Concluded with an LOI Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Amgevita (adalimumab) AMGEN CANADA INC Concluded with an LOI Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Hulio (adalimumab) BGP Pharma ULC Concluded with an LOI Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Jorveza (budesonide) AVIR Pharma Inc. Concluded without agreement eosinophilic esophagitis (induction)
Duobrii (Halobetasol propionate and tazarotene) Bausch Health, Canada Inc. Concluded with an LOI Psoriasis, moderate to severe plaque
Nexplanon (etonogestrel) Merck Canada Inc. Concluded with an LOI prevention of pregnancy
Soliris (eculizumab) Alexion Pharma GMBH Concluded without agreement Myasthenia Gravis
Zejula (Niraparib) GlaxoSmithKline Inc. Concluded with an LOI Ovarian Cancer: As monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
Xtandi (enzalutamide) Astellas Pharma Inc. Concluded with an LOI Metastatic Castration Sensitive Prostate Cancer
Cablivi (caplacizumab) sanofi-aventis Canada Inc. Negotiations were not pursued acquired thrombotic thrombocytopenic purpura (aTTP)
Rituxan SC (rituximab) Hoffmann-La Roche Concluded with an LOI Multiple Indications
Tecentriq & Avastin (Atezolizumab & Bevacizumab) HOFFMANN-LA ROCHE LIMITED Negotiations were not pursued Non-Squamous Non-Small Cell Lung Cancer
Aimovig (erenumab) NOVARTIS PHARMACEUTICALS CANADA INC Concluded without agreement migraine, chronic
Vocabria and Cabenuva (cabotegravir and rilpivirine) VIIV HEALTHCARE ULC Concluded with an LOI HIV Infection
Mayzent (siponimod) NOVARTIS PHARMACEUTICALS CANADA INC Concluded with an LOI Secondary progressive multiple sclerosis (SPMS)
Vascepa (icosapent ethyl) HLS Therapeutics Inc. Concluded with an LOI Ischemic events in statin-treated patients
Stelara (ustekinumab) Janssen Inc. Concluded without agreement Ulcerative Colitis
Soliris (eculizumab) Alexion Pharma GMBH Concluded without agreement Neuromyelitis optica spectrum disorder (NMOSD)
Darzalex SC (Daratumumab) Janssen Inc. Concluded without agreement Multiple Myeloma
Adcetris (brentuximab vedotin) Seattle Genetics Inc. Concluded with an LOI Peripheral T-Cell Lymphoma
Cuvposa (Glycopyrrolate) Medexus Pharmaceuticals, Inc. Concluded with an LOI For the reduction of pediatric chronic severe drooling (neurologic)
Xospata (Gilteritinib) Astellas Pharma Inc. Concluded with an LOI Acute Myeloid Leukemia
Aermony Respiclick (fluticasone propionate) Teva Canada Limited Concluded with an LOI Asthma
Kisqali (ribociclib) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Advanced or Metastatic Breast Cancer
Kalydeco (ivacaftor) Vertex Pharmaceuticals (Canada) Incorporated Concluded with an LOI cystic fibrosis in patients with CFTR gating mutations or the R117H gating mutation
Orkambi (lumacaftor/ivacaftor) Vertex Pharmaceuticals (Canada) Incorporated Concluded with an LOI Cystic Fibrosis, F508del CFTR mutation
Contrave (naltrexone hydrochloride and bupropion hydrochloride) Bausch Health, Canada Inc. Negotiations were not pursued Chronic weight management
Nubeqa (Darolutamide) Bayer Inc. Concluded with an LOI non-metastatic castrate resistant prostate cancer
Erleada (apalutamide) Janssen Inc. Concluded with an LOI Metastatic Castration-Sensitive Prostate Cancer
Cabometyx (cabozantinib) Ipsen Biopharmaceuticals Concluded with an LOI For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy
Crysvita (burosumab) Kyowa Kirin Canada, Inc. Concluded with an LOI X-Linked Hypophosphatemia
Entyvio (SC) (vedolizumab) Takeda Canada Inc. Concluded with an LOI Ulcerative Colitis
Dupixent (dupilumab) Sanofi Genzyme Concluded with an LOI Atopic dermatitis
Beovu (brolucizumab) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Age-Related Macular Degeneration
Benlysta (belimumab) GlaxoSmithKline Inc. Concluded with an LOI Systemic lupus erythematosus
Kisqali (with fulvestrant) (ribociclib with fulvestrant) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Advanced or Metastatic Breast Cancer
Allerject (epinephrine) Kaleo Inc Concluded with an LOI For the emergency treatment of severe acute allergic reactions (anaphylaxis).
Otezla (apremilast) Amgen Canada Inc. Concluded without agreement Psoriatic Arthritis
Otezla (apremilast) Amgen Canada Inc. Concluded without agreement Psoriasis, moderate to severe plaque
Avsola (infliximab) Amgen Canada Inc. Concluded with an LOI Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn’s disease and Ulcerative Colitis
Nivestym (filgrastim) Pfizer Canada ULC Concluded with an LOI Prevention or treatment of neutropenia in various indications
Ziextenzo (pegfilgrastim) Sandoz Canada Concluded with an LOI febrile neutropenia in non-myeloid malignancies
Redesca (enoxaparin) Valeo Pharma Inc. Concluded with an LOI Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism
Kanjinti (trastuzumab) Amgen Canada Inc. Concluded with an LOI early breast cancer/metastatic breast cancer/metastatic gastric cancer
Envarsus PA (tacrolimus) Paladin Labs Inc. Concluded with an LOI prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients
Onstryv (safinamide) Valeo Pharma Inc. Concluded with an LOI Parkinson's disease
Monoferric (iron (iii) isomaltoside 1000) Pharmacosmos A/S Concluded with an LOI iron deficiency anemia
Lokelma (sodium zirconium cyclosilicate) AstraZeneca Canada Inc. Negotiations were not pursued hyperkalemia
Taltz (ixekizumab) Eli Lilly Canada Inc. Concluded without agreement Ankylosing spondylitis
Vyndaqel (tafamidis) Pfizer Canada ULC Concluded with an LOI transthyretin-mediated amyloidosis
Rinvoq (upadacitinib) AbbVie Corporation Concluded with an LOI Rheumatoid Arthritis
Lonsurf (trifluridine/tipiracil) Taiho Pharma Canada Inc. Concluded with an LOI metastatic Gastric Cancer
Riximyo (rituximab) Sandoz Canada Concluded with an LOI Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma
Ruxience (rituximab) Pfizer Canada ULC Concluded with an LOI Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA)
Lutathera (lutetium 177 dotatate) Advanced Accelerator Applications Concluded with an LOI Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Baqsimi (glucagon) Eli Lilly Canada Inc. Concluded with an LOI severe hypoglycemia
Admelog (insulin lispro) sanofi-aventis Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 1 & 2
Lorbrena (lorlatinib) Pfizer Canada ULC Negotiations were not pursued Non-Small Cell Lung Cancer (ALK+)
Rydapt (midostaurin) Novartis Pharmaceuticals Canada Inc. Negotiations were not pursued Systemic Mastocytosis
Mylotarg (gemtuzumab ozogamicin) Pfizer Canada ULC Concluded with an LOI Acute Myeloid Leukemia
Keytruda (pembrolizumab) Merck Canada Concluded with an LOI renal cell carcinoma
Nerlynx (neratinib) Knight Therapeutics Negotiations were not pursued Hormone Receptor-Positive Breast Cancer
Cimzia (certolizumab pegol) UCB Canada Inc. Concluded without agreement Psoriasis, moderate to severe plaque
Takhzyro (lanadelumab) Concluded with an LOI Hereditary Angioedema
Revestive (teduglutide) Concluded with an LOI Short Bowel Syndrome (SBS)
Verkazia (cyclosporine) Santen Incorporated Concluded with an LOI severe vernal keratoconjunctivitis
Lonsurf (trifluridine/tipiracil) Taiho Pharma Canada Inc. Negotiations were not pursued Metastatic Colorectal Cancer
Mezera (mesalazine) AVIR Pharma Inc. Concluded with an LOI Ulcerative Colitis
Kadcyla (trastuzumab emtansine) Hoffmann-La Roche Concluded with an LOI early breast cancer
Darzalex (daratumumab) Janssen Inc. Concluded with an LOI Multiple Myeloma
Keytruda (pembrolizumab) Merck Canada Concluded with an LOI Squamous Non-Small Cell Lung Cancer
Tecentriq (atezolizumab) Hoffmann-La Roche Concluded with an LOI For the treatment of the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. Maintenance Tecentriq should be continued until loss of clinical benefit or unacceptable toxicity
Lynparza (olaparib) AstraZeneca Canada Inc. Concluded with an LOI Ovarian Cancer: As monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
Trintellix (vortioxetine) Lundbeck Canada Inc. Concluded with an LOI Major Depressive Disorder
Xultophy (insulin degludec/liraglutide) Novo Nordisk Canada Inc. Concluded without agreement Diabetes Mellitus, Type 2
Dovato (dolutegravir/lamivudine) ViiV Healthcare Concluded with an LOI HIV Infection
Iluvien (fluocinolone acetonide) Knight Therapeutics Negotiations were not pursued Diabetic Macular Edema
Emerade (epinephrine bitartrate) Bausch Health, Canada Inc. Concluded with an LOI For the emergency treatment of severe acute allergic reactions (anaphylaxis).
Bosulif (bosutinib) Pfizer Canada ULC Concluded with an LOI Chronic Myeloid Leukemia
Olumiant (baricitinib) Eli Lilly Canada Inc. Concluded with an LOI Rheumatoid Arthritis
Orfadin Oral Suspension (nitisinone) Sobi Canada Inc. Concluded without agreement Hereditary Tyrosinemia Type 1
Onpattro (patisiran) Alnylam Netherlands B.V. Concluded with an LOI hereditary transthyretin-mediated amyloidosis
Tegsedi (inotersen) Akcea Therapeutics Inc. Concluded with an LOI hereditary transthyretin-mediated amyloidosis
Truxima (rituximab) Teva Canada Limited Concluded with an LOI Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma
Vitrakvi (larotrectinib) Bayer Inc. Negotiations were not pursued Neurotrophic Tyrosine Receptor Kinase (NTRK) Locally Advanced or Metastatic Solid Tumours
Pomalyst (pomalidomide) Celgene Inc. Negotiations were not pursued Multiple Myeloma (Relapsed)
Idhifa (enasidenib) Celgene Inc. Negotiations were not pursued Acute Myeloid Leukemia
Revlimid (lenalidomide) Celgene Inc. Concluded with an LOI Multiple Myeloma
Sublocade (buprenorphine) Indivior UK Limited Concluded with an LOI Opioid Use Disorder
Cystadrops (cysteamine) Recordati Canada Concluded with an LOI corneal cystine crystal deposits
Libtayo (cemiplimab) Sanofi Genzyme Concluded with an LOI Cutaneous Squamous Cell Carcinoma
Lenvima (lenvatinib) Eisai Limited Concluded with an LOI For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy
Darzalex (daratumumab) Janssen Inc. Concluded with an LOI Multiple Myeloma (newly diagnosed)
Lutathera (lutetium 177 dotatate) Advanced Accelerator Applications Concluded without agreement Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Alunbrig (brigatinib) Takeda Canada Inc. Negotiations were not pursued Non-Squamous Non-Small Cell Lung Cancer
Ninlaro (ixazomib) Takeda Canada Inc. Negotiations were not pursued Multiple Myeloma
Verzenio (abemaciclib) Eli Lilly Canada Inc. Concluded without agreement Advanced or Metastatic Breast Cancer
Vizimpro (dacomitinib) Pfizer Canada ULC Concluded without agreement Non-Squamous Non-Small Cell Lung Cancer
Keytruda (pembrolizumab) Merck Canada Negotiations were not pursued Metastatic Urothelial Carcinoma (first line)
Keytruda (pembrolizumab) Merck Canada Concluded with an LOI Melanoma adjuvant therapy
Keytruda (pembrolizumab) Merck Canada Concluded with an LOI Non-Squamous Non-Small Cell Lung Cancer
Venclexta/rituximab (venetoclax/rituximab) AbbVie Corporation Concluded with an LOI Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible
Xalkori (crizotinib) Pfizer Canada ULC Concluded with an LOI ROS1-positive advanced Non-Small Cell Lung Cancer
Ibrance/fulvestrant (palbociclib/fulvestrant) Pfizer Canada ULC Concluded with an LOI Advanced or Metastatic Breast Cancer
Imfinzi (durvalumab) AstraZeneca Canada Inc. Concluded with an LOI Non-small Cell Lung Cancer
Tafinlar/Mekinist (dabrafenib/trametinib) Novartis Pharmaceuticals Canada Inc. Concluded with an LOI Melanoma adjuvant therapy
Trazimera (trastuzumab) Pfizer Canada ULC Concluded with an LOI early breast cancer/metastatic breast cancer/metastatic gastric cancer
Herzuma (trastuzumab) Teva Canada Limited Concluded with an LOI early breast cancer/metastatic breast cancer/metastatic gastric cancer
Ogivri (trastuzumab) BGP Pharma ULC Concluded with an LOI early breast cancer/metastatic breast cancer/metastatic gastric cancer
Opsumit (macitentan) Actelion Pharmaceuticals Ltd. Concluded with an LOI Pulmonary Arterial Hypertension
Brilinta (ticagrelor) AstraZeneca Canada Inc. Concluded with an LOI secondary prevention of atherothrombotic events
Triamcinolone Hexacetonide (triamcinolone hexacetonide) Medexus Pharmaceuticals, Inc. Concluded with an LOI Rheumatoid Arthritis
Skyrizi (risankizumab) AbbVie Corporation Concluded with an LOI Plaque psoriasis
Vyzulta (latanoprostene bunod) Bausch Health, Canada Inc. Concluded with an LOI Open-angle Glaucoma
Blincyto (blinatumomab) Amgen Canada Inc. Concluded with an LOI Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL)
Folotyn (pralatrexate) Servier Canada Inc. Concluded with an LOI Peripheral T-Cell Lymphoma
Botox (onabotulinumtoxin a) Allergan Inc. Concluded without agreement migraine, chronic
Xermelo (telotristat) Ipsen Biopharmaceuticals Negotiations were not pursued carcinoid syndorme
Jublia (efinaconazole) Bausch Health, Canada Inc. Negotiations were not pursued onychomycosis
Pifletro (doravirine) Merck Canada Inc. Concluded with an LOI HIV Infection
Delstrigo (doravirine/lamuvidine/tenofovir disoproxil fumarate) Merck Canada Inc. Concluded with an LOI HIV Infection
Cresemba (isavuconazole) AVIR Pharma Inc. Concluded with an LOI Treatment of invasive aspergillosis and mucormycosis
Unituxin (dinutuximab) United Therapeutics Concluded with an LOI neuroblastoma
Xtandi (enzalutamide) Astellas Pharma Inc. Concluded with an LOI non-metastatic castrate resistant prostate cancer
Opdivo (nivolumab) Bristol Myers Squibb Canada Inc. Concluded with an LOI Melanoma adjuvant therapy
Adcetris (brentuximab vedotin) Seattle Genetics Inc. Negotiations were not pursued Hodgkin's Lymphoma
Radicava (edaravone) Mitsubishi Tanabe Pharma Canada, Inc. Concluded with an LOI amyotrophic lateral sclerosis
Eucrisa (crisaborole) Pfizer Canada ULC Negotiations were not pursued Atopic dermatitis
Brineura (cerliponase alfa) BioMarin Pharmaceutical Inc. Concluded with an LOI neuronal ceroid lipofuscinosis type 2
Kalydeco (ivacaftor) Vertex Pharmaceuticals (Canada) Incorporated Concluded with an LOI cystic fibrosis in patients with CFTR gating mutations or the R117H gating mutation
Zirabev (bevacizumab) Pfizer Canada ULC Concluded with an LOI Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer
Spinraza (nusinersen) Biogen Canada Inc. Concluded with an LOI Spinal Muscular Atrophy
Xeljanz (tofacitinib) Pfizer Canada ULC Concluded with an LOI Ulcerative Colitis
Cabometyx (cabozantinib) Ipsen Biopharmaceuticals Concluded with an LOI renal cell carcinoma
Mvasi (bevacizumab) Amgen Canada Inc. Concluded with an LOI Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer
Ella (ulipristal acetate) Allergan Inc. Concluded with an LOI prevention of pregnancy
Segluromet (ertugliflozin/metformin hydrochloride) Merck Canada Inc. Concluded without agreement Diabetes Mellitus, Type 2
Steglatro (ertugliflozin) Merck Canada Inc. Concluded without agreement Diabetes Mellitus, Type 2
Fulphila (pegfilgrastim) BGP Pharma ULC Concluded with an LOI febrile neutropenia in non-myeloid malignancies
Xeljanz XR (tofacitinib) Pfizer Canada ULC Concluded with an LOI Rheumatoid Arthritis
Humira (citrate-free) (adalimumab citrate-free) AbbVie Corporation Concluded without agreement Multiple Indications
Ozempic (semaglutide) Novo Nordisk Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 2
Herceptin SC (trastuzumab) Hoffmann-La Roche Concluded without agreement breast cancer
Tagrisso (osimertinib) AstraZeneca Canada Inc. Concluded with an LOI first-line treatment of locally advanced or metastatic non-small cell cell lung cancer (NSCLC)
Lenvima (lenvatinib) Eisai Limited Negotiations were not pursued advanced or metastatic, clear-cell renal cell carcinoma
Harvoni (ledipasvir/sofosbuvir) Gilead Sciences Canada Inc. Concluded with an LOI Chronic Hepatitis C
Velphoro (sucroferric oxyhydroxide) Vifor Fresenius Medical Care Renal Pharma Concluded with an LOI Hyperphosphatemia, end-stage renal disease
Soliqua (lixisenatide/insulin glargine) sanofi-aventis Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 2
Perjeta/Herceptin (pertuzumab/trastuzumab) Hoffmann-La Roche Negotiations were not pursued early breast cancer
Opdivo (nivolumab) Bristol Myers Squibb Canada Inc. Negotiations were not pursued For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy
Daklinza (daclatasvir) Bristol Myers Squibb Canada Inc. Concluded with an LOI Chronic Hepatitis C
Januvia (sitagliptin phosphate) Merck Canada Inc. Concluded with an LOI Diabetes Mellitus, Type 2
Yervoy/Opdivo (nivolumab/ipilimumab) Bristol Myers Squibb Canada Inc. Concluded with an LOI renal cell carcinoma
Gazyva (obinutuzumab) Hoffmann-La Roche Negotiations were not pursued Relapsed or refractory follicular lymphoma
Erleada (apalutamide) Janssen Inc. Concluded with an LOI non-metastatic castrate resistant prostate cancer
Xarelto (rivaroxaban) Bayer Inc. Concluded with an LOI Prevention of stroke and cardiovascular events in coronary and peripheral artery disease.
Ozurdex (dexamethasone) Allergan Inc. Negotiations were not pursued Diabetic Macular Edema
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Gilead Sciences Canada Inc. Concluded with an LOI HIV infection
Fibristal (ulipristal acetate) Allergan Inc. Concluded with an LOI Intermittent treatment of moderate to severe signs and symptoms of uterine fibroids
uterine fibroids
Alecensaro (alectinib) Hoffmann-La Roche Concluded with an LOI Non-Small Cell Lung Cancer (First Line)
Praluent (alirocumab) sanofi-aventis Canada Inc. Concluded without agreement Atherosclerotic cardiovascular disease
Orkambi (lumacaftor/ivacaftor) Vertex Pharmaceuticals (Canada) Incorporated Negotiations were not pursued Cystic Fibrosis, F508del CFTR mutation
Arbesda RespiClick (fluticasone propionate/salmeterol xinafoate) Teva Canada Limited Concluded without agreement Asthma
Aermony Respiclick (fluticasone propionate) Teva Canada Limited Concluded without agreement Asthma
Viberzi (eluxadoline) Allergan Inc. Negotiations were not pursued Irritable Bowel Syndrome
Kanuma (sebelipase alfa) Alexion Pharma GMBH Concluded with an LOI Lysosomal acid lipase deficiency
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) GlaxoSmithKline Inc. Concluded with an LOI Chronic Obstructive Pulmonary Disease
Mavenclad (cladribine) EMD Serono a Division of EMD Inc. Canada Concluded with an LOI Relapsing-Remitting Multiple Sclerosis
Nucynta (tapentadol hydrochloride) Paladin Labs Inc. Negotiations were not pursued Pain, severe
Fasenra (benralizumab) AstraZeneca Canada Inc. Concluded with an LOI Eosinophilic Asthma
Dysport Therapeutic (abobotulinumtoxina) Ipsen Biopharmaceuticals Concluded with an LOI Lower Limb Spasticity
Nitisinone (nitisinone) Cycle Pharmaceuticals Ltd. Concluded with an LOI Hereditary Tyrosinemia Type 1
Taltz (ixekizumab) Eli Lilly Canada Inc. Concluded with an LOI Psoriatic Arthritis
Duodopa (levodopa/carbidopa) AbbVie Corporation Concluded with an LOI Parkinson's disease